

# Archived Document

This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of March 2017. Because of its value to the laboratory community, it is being retained in CLSI's library.



November 2011

---

## MM19-A

# Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline

This guideline provides comprehensive guidance for planning and implementation of molecular diagnostic testing, including strategic planning, regulatory requirements, implementation, quality management, and special considerations for the subspecialties of molecular genetics, infectious diseases, oncology, and pharmacogenetics.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## **Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## **Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## **Appeals Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## **Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@cls.org](mailto:standard@cls.org)

ISBN 1-56238-773-1 (Print)  
ISBN 1-56238-774-X (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

MM19-A  
Vol. 31 No. 21  
Replaces MM19-P  
Vol. 31 No. 10

---

## Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline

Volume 31 Number 21

Leslie Hall, MMSc, M(ASCP)  
Jean Amos Wilson, PhD, FACMG, CGMB  
Kathy Bernard, MSc, ARM(CCM)  
Michele P. Carbone, MS, CLS(ASCP) SH  
Haja Sittana El Mubarak, PhD  
Stephanie E. Hallam, PhD, FACMG, MBA  
Roger D. Klein, MD, JD, FCAP  
Preeti Pancholi, PhD, D(ABMM)  
Michele M. Schoonmaker, PhD  
Elaine B. Spector, PhD, FACMG  
Patrik Vitazka, MD, PhD

Jerry Boonyaratanakornkit, MS  
Bonita Bryant, MT(ASCP), CLSpMB(NCA)  
Jianli Dong, MD, PhD, FACMG  
Rajyasree Emmadi, MD, FCAP  
Manohar R. Furtado, PhD  
Felicitas Lacbawan, MD, FCAP, FACMG  
Francisco Martinez-Murillo, PhD  
Ted E. Schutzbank, PhD, D(ABMM)  
Rangaraj Selvarangan, BVSc, PhD, D(ABMM)  
Venkatakrishna Shyamala, PhD  
Laurina O. Williams, PhD, MPH  
Alan Wu, PhD, DABCC

### Abstract

Clinical and Laboratory Standards Institute document MM19-A—*Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline* provides a framework for decision making and implementation of clinical molecular diagnostics, and is intended for those in established clinical laboratories that are implementing a molecular program for the first time. When implementing any diagnostic test for patient care, many elements should be addressed before the test is brought “online.” This document focuses on the path of workflow, including laboratory safety and the quality management system, with emphasis on considerations for molecular diagnostics. An organized approach to strategic planning with SWOT (strengths, weaknesses, opportunities, and threats) is presented. Relevant regulatory requirements and the implementation plan are discussed in detail.

Importantly, separate sections are devoted to each of the following subspecialty areas: heritable diseases, oncology and malignant hematology, pharmacogenomics, and infectious diseases. Each of these sections addresses special considerations for molecular testing for each subspecialty.

Clinical and Laboratory Standards Institute (CLSI). *Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline*. CLSI document MM19-A (ISBN 1-56238-773-1 [Print]; ISBN 1-56238-774-X [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2011.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@cls.org](mailto:customerservice@cls.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2011 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline*. CLSI document MM19-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

### **Previous Edition:**

May 2011

### **Archived:**

March 2017

ISBN 1-56238-773-1 (Print)

ISBN 1-56238-774-X (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

## Committee Membership

### Consensus Committee on Molecular Methods

**Roberta M. Madej, CLS, MS,  
MBA**  
**Chairholder**  
**Cepheid**  
**Sunnyvale, California, USA**

**Frederick S. Nolte, PhD**  
**Vice-Chairholder**  
**Medical University of South  
Carolina**  
**Charleston, South Carolina, USA**

Stephen P. Day, PhD  
Hologic, Inc.  
Madison, Wisconsin, USA

Lisa Kalman, PhD  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia, USA

Penny Keller, BS, MP(ASCP)  
Centers for Medicare & Medicaid  
Services  
Baltimore, Maryland, USA

Deborah Payne, PhD  
APP-Uni-Path  
Denver, Colorado, USA

Zivana Tezak-Fragale, PhD  
FDA Center for Devices and  
Radiological Health  
Silver Spring, Maryland, USA

Jean Amos Wilson, PhD, FACMG,  
CGMB  
Berkeley HeartLab, Inc.  
Alameda, California, USA

Emily S. Winn-Deen, PhD  
Illumina, Inc.  
San Diego, California, USA

### Document Development Committee on Establishing Molecular Testing in Clinical Laboratory Environments

**Leslie Hall, MMSc, M(ASCP)**  
**Co-Chairholder**  
**Mayo Clinic**  
**Rochester, Minnesota, USA**

**Jean Amos Wilson, PhD,  
FACMG, CGMB**  
**Co-Chairholder**  
**Berkeley HeartLab, Inc.**  
**Alameda, California, USA**

Kathy Bernard, MSc, ARM(CCM)  
National Microbiology Laboratory,  
PHAC  
Winnipeg, Canada

Michele P. Carbone, MS,  
CLS(ASCP) SH  
Redondo Beach, California, USA

Haja Sittana El Mubarak, PhD  
FDA Center for Devices and  
Radiological Health  
Silver Spring, Maryland, USA

Stephanie E. Hallam, PhD,  
FACMG, MBA  
Good Start Genetics  
Boston, Massachusetts, USA

Roger D. Klein, MD, JD, FCAP  
BloodCenter of Wisconsin  
Milwaukee, Wisconsin, USA

Preeti Pancholi, PhD, D(ABMM)  
The Ohio State University Medical  
Center  
Columbus, Ohio, USA

Mario Pazzagli, PhD  
University of Florence  
Florence, Italy

Michele M. Schoonmaker, PhD  
Cepheid  
Sunnyvale, California, USA

Elaine B. Spector, PhD, FACMG  
University of Colorado Denver,  
School of Medicine  
Aurora, Colorado, USA

Patrik Vitazka, MD, PhD  
Merck Sharp & Dohme Idea, Inc.  
Bratislava, Slovakia

#### Staff

Clinical and Laboratory Standards  
Institute  
Wayne, Pennsylvania, USA

Luann Ochs, MS  
*Vice President, Standards  
Development*

Tracy A. Dooley, BS, MLT(ASCP)  
*Staff Liaison*

Marcy Hackenbrack, MCM,  
M(ASCP), BA  
*Project Manager*

Megan P. Larrisey, MA  
*Editor*

### Acknowledgment

CLSI and the Consensus Committee on Molecular Methods gratefully acknowledge the following individuals for their help in preparing this document:

Jerry Boonyaratanakornkit, MS  
AcroMetrix Corporation  
Benicia, California, USA

Francisco Martinez-Murillo, PhD  
FDA Center for Devices and Radiological Health  
Silver Spring, Maryland, USA

Bonita Bryant, MT(ASCP), CLSpMB(NCA)  
Access Genetics  
Minneapolis, Minnesota, USA

Ted E. Schutzbank, PhD, D(ABMM)  
Covance Central Laboratory Services  
Indianapolis, Indiana, USA

Jianli Dong, MD, PhD, FACMG  
University of Texas Medical Branch  
Galveston, Texas, USA

Rangaraj Selvarangan, BVSc, PhD, D(ABMM)  
Children's Mercy Hospital  
Kansas City, Missouri, USA

Rajyasree Emmadi, MD, FCAP  
University of Illinois At Chicago  
Chicago, Illinois, USA

Venkatakrishna Shyamala, PhD  
Consultant, Molecular Diagnostics and Blood  
Screening  
North Potomac, Maryland, USA

Manohar R. Furtado, PhD  
Life Technologies/Applied Biosystems  
Foster City, California, USA

Laurina O. Williams, PhD, MPH  
Centers for Disease Control and Prevention  
Atlanta, Georgia, USA

Felicitas Lacbawan, MD, FCAP, FACMG  
CAP Biochemical and Molecular Genetics  
Subcommittee  
Northfield, Illinois, USA

Alan Wu, PhD, DABCC  
San Francisco General Hospital  
San Francisco, California, USA

CLSI and the Consensus Committee on Molecular Methods gratefully acknowledge the following individuals for their help in preparing Section 11.1.5.6, Chimerism Testing:

Douglas A. Bost, BA  
Celera Corporation  
Alameda, California, USA

Ian J. McLaughlin, BA  
Celera Corporation  
Alameda, California, USA

Jan Capper, BA, CHS(ABHI)  
Celera Corporation  
Alameda, California, USA

**Contents**

Abstract.....i

Committee Membership..... iii

Foreword..... vii

1 Scope.....1

2 Introduction.....2

3 Standard Precautions.....3

4 Terminology.....3

    4.1 A Note on Terminology .....3

    4.2 Definitions .....4

    4.3 Abbreviations and Acronyms .....15

5 Safety .....19

    5.1 Standard Precautions.....19

    5.2 Biological Hazards.....20

    5.3 Chemical Hazards .....20

    5.4 Radiation Hazards.....21

    5.5 Ultraviolet Light Hazards .....21

    5.6 Electrical Hazards .....22

6 Strategic Planning .....22

    6.1 A Strategic Planning Tool.....22

    6.2 Examples of SWOT Analysis .....27

7 Patient Samples and Nucleic Acid Extraction .....31

    7.1 Patient Samples.....31

    7.2 Specimen Processing and Preparation for Nucleic Acid Extraction .....36

    7.3 Nucleic Acid Extraction.....37

    7.4 Nucleic Acid Extraction Methods.....39

8 Implementation Plan .....40

    8.1 Facilities for Target Amplification .....40

    8.2 Equipment.....46

    8.3 Laboratory Information System Interface.....48

    8.4 Workflow .....48

    8.5 Procedures/Instructions (Standard Operating Procedures) .....49

    8.6 Reference Materials .....49

    8.7 Verification and Validation.....52

    8.8 Results and Data Analysis .....56

9 Quality Management System .....60

10 Developing a Quality Management System.....60

    10.1 Components of the Quality Management System Unique to Molecular Testing .....61

    10.2 Proficiency Testing (External Quality Assessment) .....69

**Contents (Continued)**

10.3	Specific Postexamination Considerations: Clinical Interpretation of Patient Test Results.....	71
11	Unique Considerations for Different Laboratory Specialties.....	72
11.1	Heritable Diseases.....	72
11.2	Oncology and Malignant Hematology.....	101
11.3	Pharmacogenomics .....	111
11.4	Infectious Diseases .....	116
	References.....	155
	Appendix A. Regulatory Requirements .....	179
	Appendix B. Technology Overview and Platforms .....	210
	Appendix C. Examples of Technology Available to Detect Infectious Diseases .....	232
	The Quality Management System Approach .....	234
	Related CLSI Reference Materials .....	236



## **Foreword**

This guideline was written in response to the growing migration of common molecular diagnostic tests from solely esoteric laboratories to the more routine clinical environment. Molecular assays are becoming more attractive to routine clinical laboratories based on the availability of *in vitro* diagnostic devices and the relative ease of their implementation. Incorporating molecular testing into the routine menu decreases the need for sendouts, thus improving turnaround time and the financial health of the laboratory.

## **Key Words**

Molecular diagnostics, molecular genetics, molecular hematopathology, molecular infectious disease, molecular regulatory requirements, strategic planning, unidirectional workflow



## **Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline**

### **1 Scope**

This document was written by experienced molecular laboratory professionals to provide an introduction to molecular diagnostics for nonmolecular, routine clinical laboratories, as well as a framework for decision making and implementation of molecular testing. The target audience of this guideline is the stakeholders who play a role in the strategic decision to implement a molecular diagnostic program, including the:

- Medical and technical directors who may not have previous experience with molecular testing
- Supervisory technical staff who implement molecular assays for the first time
- Quality management systems (QMS) group who will adapt the quality plan to incorporate the unique aspects of the new program
- Production staff that will perform and maintain all aspects of the assays

Because molecular diagnostics encompasses a very broad area, this document focuses on clinical applications and technologies most likely to be used in a laboratory that is venturing into molecular testing for the first time. The laboratory may have a concentration in a specific subspecialty (eg, microbiology) or not. However, given that this document is written for nonmolecular experts, several more complex areas of molecular testing were excluded from the scope, including:

- Complex technologies, including, but not limited to, laboratory-developed tests (LDTs) that require primer and/or probe design, proteomics, pulsed-field gel electrophoresis, multiple locus sequence testing, and repetitive extragenic palindromic sequence-based polymerase chain reaction (PCR)
- Complex reflex testing algorithms
- Laboratory tests that require a high degree of clinical expertise to interpret, such as donor-recipient compatibility typing, and molecular typing of strains possibly related in an outbreak
- Tests for sexual abuse and forensics
- Tests of the blood and tissue supply (eg, blood banks)

It is also out of the scope of this guideline to consider assays that should remain in specialized or esoteric testing facilities, such as:

- Methods for detecting pathogens such as bioterrorism agents that require biosafety levels (BSL) 3 or greater, which are otherwise handled in specialized facilities
- Prenatal diagnosis and preimplantation genetic diagnosis (PGD) of heritable disease